World Alzheimer’s Day 2022

An estimated 50 million people around the world currently live with Alzheimer's disease or other dementias, dementia being a collective term for progressive syndromes that affect various expressions of cognitive function, such as memory and emotional expression. Alzheimer’s disease accounts for the majority of cases (50 to 70%, varying by country, based on Alzheimer’s Disease International and World Health Organization figures). For those directly affected and their loved ones, dementia can be a frightening experience, particularly as it is so poorly understood. However there remains little or no understanding of dementia in many, and the stigmatization and misinformation that surrounds dementia remains a global issue.

For 2022 World Alzheimer’s Day the theme Know Dementia, Know Alzheimer’s, organized annually by Alzheimer’s Disease International, focuses on diagnosis, the warning signs of dementia, with a special focus on post-diagnosis support. The aim of this international campaign is to highlight the importance of support for people living with dementia and families following a diagnosis.

Percentage change between 2019 and 2050 in all-age number of individuals with dementia by country.
Elsevier,

The Lancet Public Health, Volume 7, February 2022

An article on the global prevalence of dementia, in the context of SGD 3, focusing specifically on forecasting country-level estimates of dementia prevalence attributable to high BMI, high fasting glucose, and smoking, from 2019 to 2050.
Elsevier,

American Journal of Medicine, Volume , 2022

Higher dietary fiber intake is associated with improved specific components of cognitive function in older adults aged 60 years and older. 
Elsevier,

The Lancet Neurology, Volume 20, November 2021

An article on treatment for Alzheimer's disease, in the context of SDG 3, focusing specifically on whether an angiotensin II receptor antagonist can reduce brain volume loss.
Elsevier,

The Lancet Infectious Diseases, Volume 21, November 2021

An article, in the context of SDG 3, analysing the risk of Alzheimer's disease and other dementias across a range of hospital-treated bacterial and viral infections in two large cohorts.
Elsevier,

Journal of Clinical Densitometry, Volume 24, 1 October 2021

Alzheimer's disease is a strong predictor in survival after hip fracture surgery.
Elsevier,

Behavioural Brain Research, Volume 414, 24 September 2021

Reelin deficiency when combined with AD risk-factors produced consistent impairments in spatial memory tasks. Furthermore, the results further implicate Reelin’s importance in both HF homeostasis and AD pathogenesis.
Elsevier,

EBioMedicine, Volume 71, September 2021

An article on the pathology of Alzheimer's disease, in the context of SDG 3, focusing specifically on the potential use of an anti-cancer drug to modulate cerebrovascular angiogenesis as an alternative therapeutic strategy.
Elsevier,

EClinicalMedicine, Volume 39, September 2021

An article on the detrimental effects of COVID-19 isolation on the cognitive and mental health of people with dementia, in the context of SDGs 3 and 10, highlighting the need for guidance that balances infection control measures with principles of non-maleficence to appropriately care for this patient group.
Schematic representations of the properties and functions of metal chelating agents.
Elsevier,

Journal of Trace Elements in Medicine and Biology, Volume 67, September 2021

Hypotheses for the pathogenesis of Alzheimer’s disease (AD) are described in this paper. The review is intended to be a basic and encyclopedic short insight into metals in AD and discusses the advances in chelation strategies and developments adopted in the treatment of the disease.
Elsevier, The Lancet Healthy Longevity, Volume 2, August 2021
Background: People with dementia die prematurely. Identifying differences in mortality rates between different types of dementia might aid in the development of preventive interventions for the most vulnerable populations. The aim of this study was to compare the difference in mortality rates between individuals without dementia and individuals with various types of dementia.

Pages